‘Excellent’ survival with HCT despite early treatment failure in FL

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
Autologous and allogeneic hematopoietic stem cell transplantation (HCT) both offer excellent long-term survival in follicular lymphoma (FL) patients who experience early treatment failure, an analysis of a large transplant registry suggests. Five-year survival rates exceeded 70% for patients who received autologous or matched sibling donor (MSD) transplants, according to... [Read Article]
Print Friendly, PDF & Email

Dasatinib outcomes similar to imatinib in pediatric Ph+ ALL

Print Friendly, PDF & Email


Child with leukemia
Photo by Bill Branson
Dasatinib used during induction and consolidation in the Children’s Oncology Group (COG) AALL0622 trial provided early response rates for children with Ph-positive (Ph+) acute lymphoblastic leukemia (ALL), according to investigators. But the early response rates did not improve event-free survival (EFS) compared to the use of consolidation... [Read Article]
Print Friendly, PDF & Email

Cytotect®CP found to be safe and effective after allo-HCT

Print Friendly, PDF & Email


Micrograph showing
CMV infection
A small retrospective study of 23 transplant patients has confirmed that CMV hyperimmune globulin (Cytotect®CP) is a safe and effective salvage therapy for patients with cytomegalovirus (CMV) infection after allogeneic hematopoietic cell transplant (allo-HCT). Cytotect®CP used as salvage therapy resulted in a 78% overall response rate and 70% of all... [Read Article]
Print Friendly, PDF & Email

A closer look at the BK polyomavirus

Print Friendly, PDF & Email


Structure of the BK polyomavirus
Photo credit: University of Leeds
A detailed image at near-atomic levels of the BK polyomavirus (BKV), which affects kidney and bone marrow transplant patients, is now available for the first time. This molecular-level structural visualization could allow scientists to study potential targets for antiviral therapies or drugs. BKV... [Read Article]
Print Friendly, PDF & Email

Older, cheaper drug formulation to remain available

Print Friendly, PDF & Email


Imbruvica (ibrutinib)
Photo courtesy of Janssen
The 140 mg capsules of Imbruvica® (ibrutinib) will remain on the market, according to Pharmacyclics LLC. Pharmacyclics (an AbbVie company) and Janssen had planned to discontinue the capsules after introducing a single-tablet formulation of Imbruvica earlier this year. However, the companies received negative feedback about the discontinuation... [Read Article]
Print Friendly, PDF & Email

MSC product can treat refractory GVHD

Print Friendly, PDF & Email


Mesenchymal stem cells
Results from a phase 3 trial suggest a mesenchymal stem cell (MSC) product can treat steroid-refractory, acute graft-versus-host disease (GVHD) in children. The product, remestemcel-L (MSC-100-IV), produced an overall response rate of 69% at day 28, with complete resolution of GVHD in 29% of patients. Adverse events (AEs) in this trial... [Read Article]
Print Friendly, PDF & Email

CAR T-cell therapy bridges to HSCT in AML patient

Print Friendly, PDF & Email


HSCT preparation
Photo by Chad McNeeley
A case report suggests an investigational chimeric antigen receptor (CAR) T-cell therapy can provide a bridge to transplant in relapsed/refractory acute myeloid leukemia (AML). The therapy, known as CYAD-01, prompted a morphologic leukemia-free state in an AML patient. This patient went on to receive an allogeneic hematopoietic... [Read Article]
Print Friendly, PDF & Email

JAK inhibitor reduces GVHD in mice

Print Friendly, PDF & Email


Micrograph showing GVHD
Image from PLOS ONE
An investigational JAK1/2 inhibitor can fight graft-versus-host disease (GVHD), according to preclinical research published in Leukemia. The inhibitor, baricitinib, reduced GVHD in mice while preserving T-cell expansion and the graft-versus-leukemia (GVL) effect. Baricitinib proved more effective than ruxolitinib for the treatment and prevention of GVHD and... [Read Article]
Print Friendly, PDF & Email

Haplo-HSCT regimen can cure SCD, team says

Print Friendly, PDF & Email


Damiano Rondelli, MD
Photo from University
of Illinois at Chicago/
Jenny Fontaine
A haploidentical transplant regimen has led to long-term engraftment in adults with sickle cell disease (SCD), according to researchers. Seven of 8 patients treated with this regimen were still alive at last follow-up, and 6 of them maintained engraftment. Two patients developed... [Read Article]
Print Friendly, PDF & Email